Ranolazine 500 mg
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Atherosclerotic Coronary Vascular Disease
Conditions
Atherosclerotic Coronary Vascular Disease
Trial Timeline
Mar 9, 2012 → Jan 2, 2014
NCT ID
NCT01562041About Ranolazine 500 mg
Ranolazine 500 mg is a phase 2 stage product being developed by Novartis for Atherosclerotic Coronary Vascular Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT01562041. Target conditions include Atherosclerotic Coronary Vascular Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01562041 | Phase 2 | Terminated |
Competing Products
20 competing products in Atherosclerotic Coronary Vascular Disease